BioSpace News Archive

ARUP Laboratories today released the company’s public comment on the FDA’s proposed rule to regulate laboratory-developed tests (LDTs) as medical devices, urging the agency to withdraw the rule.

OncoResponse today announced the dosing of the first participant in the Phase 1/2 trial of OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression.

ENDRA Life Sciences Secures 39 th U.S. Patent for TAEUS ® System Technology.

Ferring Pharmaceuticals today announced the presentation of new 36-month follow-up data from the Phase 3 study at the 24th Annual Meeting of the Society of Urologic Oncology (SUO) demonstrating a sustained durability of response with ADSTILADRIN® (nadofaragene firadenovec-vncg) in adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).

BiVACOR, Inc. today announced the United States Food and Drug Administration (FDA) has provided approval for The BiVACOR Total Artificial Heart (BTAH) to commence an investigational device exemption (IDE) for the first-in-human Early Feasibility Study (EFS).

Wiley will release its second quarter 2024 results prior to market open on Wednesday, December 6, 2023.

Phenomic AI (“Phenomic”) today announced that they have entered into a strategic collaboration and licensing agreement with Boehringer Ingelheim to discover targets important in stroma-rich cancers.

Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $100M.

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced positive results from a Phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of Age-Related Macular Degeneration (AMD).

Nascent Biotech, Inc. is pleased to announce the Company has been issued a patent from the Japanese Patent Office for its primary asset, Pritumumab.